AI Article Synopsis
Article Abstract
Introduction: The 2024 Voice AI Symposium, hosted by the Bridge2AI-Voice Consortium in Tampa, FL, featured two keynote speeches that addressed the intersection of voice AI, healthcare, ethics, and law. Dr. Rupal Patel and Dr. Nicholson Price provided insights into the advancements, applications, and challenges of AI-driven voice tools in healthcare. The symposium aimed to advance cross-disciplinary collaboration and establish frameworks for the ethical use of AI technologies in healthcare.
Methods: The keynote speeches, delivered on May 1st and 2nd, were 30 minutes each, followed by 10-minutes Q&A sessions. The audio was recorded and transcribed using Whisper (v7.13.1). Content summaries were generated with the aid of ChatGPT (v4.0), and the authors reviewed and edited the final transcripts to ensure accuracy and clarity.
Results: Dr. Rupal Patel's keynote, "Reflections and New Frontiers in Voice AI", explored the potential of voice AI for early detection of health conditions, monitoring disease progression, and promoting non-invasive global health management. She highlighted innovative uses beyond traditional applications, such as examining menopause-related symptoms. Dr. Nicholson Price's keynote, "Governance for Clinical Voice AI", addressed the regulatory and ethical challenges posed by AI in healthcare. He stressed the need for context-aware systems and dynamic legal frameworks to address liability and accountability.
Conclusions: The 2024 Voice AI Symposium highlighted the transformative potential of voice AI for early detection, health monitoring, and reducing healthcare disparities. It also underscored the importance of dynamic governance to address the ethical and regulatory challenges of deploying AI in clinical settings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11649621 | PMC |
| http://dx.doi.org/10.3389/fdgth.2024.1484503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Summary of Keynote Speeches from the 2024 Voice AI Symposium, presented by the Bridge2AI-Voice Consortium.
Front Digit Health
December 2024
Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, United States.
Introduction: The 2024 Voice AI Symposium, hosted by the Bridge2AI-Voice Consortium in Tampa, FL, featured two keynote speeches that addressed the intersection of voice AI, healthcare, ethics, and law. Dr. Rupal Patel and Dr.
View Article and Find Full Text PDFReport on the 4th Board Meeting of the International Human Phenome Consortium.
Phenomics
June 2024
Human Phenome Institute, Fudan University, Shanghai, 200438 China.
Article Synopsis
- The Board of International Human Phenome Consortium (IHPC) is instrumental in guiding the global Human Phenome Project, focusing on large-scale biomedicine research to understand human phenomes.* -
- A recent virtual meeting showcased advancements in phenomics, including the development of the first human phenome Atlas, which aids in understanding limb growth, disease prevention, and early diagnosis.* -
- The board discussed frameworks for phenome measurements, the PhenoBank Initiative, and the importance of standardized platforms and databases for efficient research collaboration.*
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
Eur J Cancer
November 2024
Gustave Roussy Cancer Campus Grand Paris & University Paris-Saclay, Villejuif, France.
Article Synopsis
- A phase 3 trial found that 12 months of adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with high-risk stage III melanoma compared to placebo, with longer follow-up data available.
- With a median follow-up of 6.9 years, the pembrolizumab group showed a 50% RFS at 7 years versus 36% for the placebo group, and a 54% DMFS compared to 42% in the placebo group.
- The results indicated consistent positive outcomes across various melanoma subtypes, confirming the long-term benefits of pembrolizumab in improving survival metrics in these patients.
Case identification and healthcare utilization in the years prior to a first mania diagnosis.
J Affect Disord
November 2024
Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA, United States of America; Department of Health Care Policy, Harvard Medical School, Boston, MA, United States of America.
Article Synopsis
- The study looked at how to find people who were newly diagnosed with bipolar disorder and had episodes of mania by using a big database in Massachusetts.
- Researchers found 583 young individuals who seemed to have new bipolar disorder diagnoses in 2016, and many had seen doctors for other issues before their diagnosis.
- The research showed that it's important to look at a lot of medical history from different sources to correctly identify new cases of bipolar disorder with mania.
Self-reported attention and responses to cigarette package labels at the end of a two-week randomized trial of cigarette package labeling configurations.
Tob Induc Dis
June 2024
Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, United States.
Introduction: Cigarette package inserts that describe quitting benefits and tips may promote cessation; however, research is needed to understand better their effects, including potentially enhancing the effects of pictorial health warning labels (PHWLs).
Methods: A randomized trial with a 2×2 factorial design was conducted with adult smokers (n=356) assigned to either small text-only health warning labels (HWLs; control); inserts with cessation messages, and the small text-only HWLs (inserts-only); large PHWLs (PHWLs-only); both inserts and PHWLs (inserts + PHWLs). Participants received a 14-day supply of their preferred cigarettes with packs labeled to reflect their group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!